FIGURE 4.
AD-1526: dupilumab in adolescents with moderate-to-severe AD in AD-1526.62 Dupilumab was significantly more effective than control for both primary endpoints (percentage achieving an IGA score of 0 or 1 and percentage achieving EASI-75). AD, Atopic dermatitis; EASI, Eczema Area and Severity Index; IGA, Investigator Global Assessment.